Physician profile
James Sun
NPI 1003278391
$2,931.15
in general payments reported to CMS, 2019-2025
12 companies · $92.34 in 2025
The $92.34 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $673 · 2023: $151 · 2024: $146 · 2025: $92.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,056.44 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $242.51 | 2019 | |
| Merck Sharp & Dohme LLC | $138.87 | 2019-2025 | Keytruda |
| La Jolla Pharmaceutical Company | $123.34 | 2023 | Xerava |
| Springworks Therapeutics, INC. | $121.60 | 2024 | Ogsiveo |
| Allergan, INC. | $72.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.74 | 2019 | |
| Gilead Sciences, INC. | $37.78 | 2025 | |
| Stryker Corporation | $27.58 | 2023 | Clarifix Cryotherapy Device |
| Glaxosmithkline, LLC. | $24.88 | 2024 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $21.67 | 2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $14.34 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.